Clinical trial • Not applicable • Neurology

Botulinum toxin type A - haemagglutinin complex for Dystonic tremor syndrome

Not applicable trial of Botulinum toxin type A - haemagglutinin complex for Dystonic tremor syndrome. 60 participants.

Overview

Trial Therapeutic Area
Neurology
Trial Disease
Dystonic tremor syndrome
Trial Stage
Not applicable
Drug Modality
Peptide/protein/enzyme

Key dates

Initial CTIS Submission Date
14-08-2024
First CTIS Authorization Date
11-11-2024

Trial design

Not applicable trial across 3 sites in Netherlands.

Target Sample Size
60

Eligibility

Recruits 60 No vulnerable population selected; only adults (Age ≥ 18 years). Subject information and informed consent form for adults available (L1_SIS and ICF adults public)..

Pregnancy Exclusion
Pregnancy, trying to conceive and breastfeeding
Vulnerable Population
No vulnerable population selected; only adults (Age ≥ 18 years). Subject information and informed consent form for adults available (L1_SIS and ICF adults public).

Inclusion criteria

  • {"criterion_text":"- Clinical diagnosis of dystonic tremor or tremor associated with dystonia according to the 2018 consensus statement on the classification of tremors"}
  • {"criterion_text":"- Tremor of one or both upper extremities"}
  • {"criterion_text":"- Starting botulinum neurotoxin injections as part of normal clinical practice"}
  • {"criterion_text":"- Age ≥ 18 years"}

Exclusion criteria

  • {"criterion_text":"- Acquired aetiology of dystonic tremor syndrome"}
  • {"criterion_text":"- Previous botulinum neurotoxin treatment of the to be treated upper extremity for ≥ 4 consecutive sessions"}
  • {"criterion_text":"- In case of previous botulinum neurotoxin treatment of the to be treated upper extremity for ≤3 consecutive sessions: the last botulinum neurotoxin injections ≤ 6 months before study enrolment"}
  • {"criterion_text":"- Unstable dose medications for dystonia and tremor ≤ 1 month before study enrolment"}
  • {"criterion_text":"- Deep brain stimulation implantation ≤ 6 months before study enrolment"}
  • {"criterion_text":"- Unstable deep brain stimulation variables ≤ 1 month before study enrolment"}
  • {"criterion_text":"- Comorbidity interfering with study participation"}
  • {"criterion_text":"- Known hypersensitivity for components of Dysport"}
  • {"criterion_text":"- Infection at the upper extremity"}
  • {"criterion_text":"- Pregnancy, trying to conceive and breastfeeding"}
  • {"criterion_text":"- Insufficient knowledge of the Dutch or English language"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The associations between clinical (e.g. dystonic tremor versus tremor associated with dystonia, jerkiness, dominant tremor pattern, sensory trick), electrophysiological (e.g. frequency-width at half-width power, intermuscular coherence), ultrasonographic (e.g. echogenicity, muscle thickness, tremulous muscles) and (functional) magnetic resonance imaging tremor characteristics (e.g. ratio of tremor-related activity in the basal ganglia versus cerebello-thalamo-cortical circuit)","definition_or_measurement_approach":"Associations assessed across clinical assessments (phenotype features such as jerkiness, dominant tremor pattern, sensory trick), electrophysiological measures (e.g. frequency-width at half-width power, intermuscular coherence), ultrasonographic measures (echogenicity, muscle thickness, identification of tremulous muscles) and (functional) MRI measures (e.g. ratio of tremor-related activity in basal ganglia vs cerebello-thalamo-cortical circuit) in relation to botulinum neurotoxin efficacy."}

Secondary endpoints

  • {"endpoint_text":"- The clinical, electrophysiological, ultrasonographic and (functional) magnetic resonance imaging differences between dystonic tremor and tremor associated with dystonia at baseline (e.g. jerkiness, dominant tremor pattern, frequency-width at half-width power, intermuscular coherence, tremulous muscles, ratio of tremor-related activity in the basal ganglia versus cerebello-thalamo-cortical circuit).","definition_or_measurement_approach":"Baseline comparisons using clinical assessments, electrophysiological measures (frequency-width at half-width power, intermuscular coherence), ultrasonography (tremulous muscles) and (f)MRI (ratio of tremor-related activity) between dystonic tremor and tremor associated with dystonia."}
  • {"endpoint_text":"- The agreement between a clinical assessment, polymyography and muscle ultrasound on muscle selection","definition_or_measurement_approach":"Agreement analysis between clinical muscle selection, polymyography results and muscle ultrasound findings for selection of muscles to treat."}

Recruitment

Planned Sample Size
60
Recruitment Window Months
29
Consent Approach
Informed consent is required from adult participants (Age ≥ 18 years). A subject information sheet and informed consent form for adults is listed (L1_SIS and ICF adults public). No assent procedures described.

Geography

Total Number Of Sites
3
Total Number Of Participants
60

Netherlands

Earliest CTIS Part Ii Submission Date
27-08-2024
Latest Decision Or Authorization Date
11-11-2024
Processing Time Days
76
Number Of Sites
3
Number Of Participants
60

Sites

Site Name
Canisius Wilhelmina Ziekenhuis
Department Name
Neurology
Contact Person Name
Frouke Nijhuis
Contact Person Email
f.nijhuis@cwz.nl
Site Name
Radboud universitair medisch centrum / RADBOUDUMC
Department Name
Neurology
Contact Person Name
Anke Snijders
Contact Person Email
anke.snijders@radboudumc.nl
Site Name
Radboud Universiteit Nijmegen
Department Name
Donders Centre for Cognitive Neuroimaging
Contact Person Name
Rick Helmich
Contact Person Email
rick.helmich@radboudumc.nl

Sponsor

Primary sponsor

Full Name
Stichting Radboud universitair medisch centrum
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Netherlands

Third parties

  • {"country":"","full_name":"Radboud University Medical Centre","duties_or_roles":"Source of monetary support","organisation_type":""}
  • {"country":"","full_name":"Canisius-Wilhelmina Hospital","duties_or_roles":"Source of monetary support","organisation_type":""}

Investigational products

Investigational Product Name
Dysport 300 E, poeder voor oplossing voor injectie
Active Substance
Botulinum toxin type A - haemagglutinin complex
Modality
Peptide/protein/enzyme
Routes Of Administration
INJECTION
Route
INJECTION
Authorisation Status
Authorised (marketing authorisation RVG 110868, NL)
Maximum Dose
1000 U unit(s)

Related trials

Other published trials that may interest you.